AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06769516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular Vagus Nerve Stimulation (aVNS)
Description: This intervention involves transcutaneous auricular vagus nerve stimulation (taVNS) using the VagusStim device. The device consists of earphones tailored to fit the individual's ear size (S, M, L) and is connected to a TENS unit. The stimulation is applied to the tragus and concha of the ear for 30 minutes, three times a week, over a 4-week period. The device operates with a pulse duration of less than 500 microseconds, a frequency of 10 Hz, and in a modulated TENS mode. The current intensity is individually adjusted to the participant's sensory threshold. This method targets the vagus nerve to potentially regulate autonomic activity and improve symptoms of Irritable Bowel Syndrome (IBS).~The study combines this intervention with a low FODMAP diet for all participants, distinguishing it from studies focused solely on vagus nerve stimulation or dietary changes.
Study NCT06769516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise Therapy
Description: This intervention involves a structured aerobic exercise program designed to improve physical activity levels and modulate symptoms of Irritable Bowel Syndrome (IBS). Participants engage in walking exercises at a moderate intensity, maintaining 50-70% of their maximum heart rate, ensuring the ability to converse comfortably during the activity. The exercise sessions last for at least 30 minutes, three days a week, on alternate days, over a 4-week period.~Participants are individually trained and monitored to ensure proper technique and adherence to the exercise protocol. The intervention is combined with a low FODMAP diet, providing a multimodal approach to IBS symptom management. This distinguishes it from other interventions by emphasizing physical activity's role in enhancing gastrointestinal and overall health.
Study NCT06769516 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet Intervention
Description: This intervention involves the implementation of a low FODMAP (fermentable oligo-, di-, mono-saccharides, and polyols) diet to manage symptoms of Irritable Bowel Syndrome (IBS). Participants receive individualized training on the diet before the study begins. The diet eliminates high FODMAP foods known to exacerbate IBS symptoms, such as certain fruits, vegetables, dairy products, and sweeteners, for a duration of 4 weeks.~Participants follow the prescribed dietary protocol under guidance, ensuring adherence and addressing specific nutritional needs. This intervention aims to reduce gastrointestinal distress by limiting fermentable carbohydrates, distinguishing it from other IBS management strategies that do not focus on dietary modifications.
Study NCT05236374 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Beef protein
Description: Animal protein source
Study NCT05236374 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Beef protein
Description: Animal protein source
Study NCT05996341 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: blood flow restriction
Description: 12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
Study NCT05996341 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: blood flow restriction
Description: 12 lower ribs and upper rechargeable nylon ribs (84 cm long, 14 cm long) Points), recharge to 160mmHg
Study NCT05830734 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: injection of freshly collected adipose cells
Description: A small incision is made bilaterally in the lumbar region. 2-300 ml of Ringer's acetate with 1 mg of added adrenaline is introduced with an infusion cannula fan-shaped into the subcutaneous adipose tissue on each side of the region.~Adipose tissue is harvested for a total of approx. 80 ml. 20 ml Bupivacaine 5 mg/ml is distributed on each side of the lower back. The incisions are then closed with Steri-Strips and a compressive dressing is applied to reduce the risk of hematoma.~The harvested adipose tissue then centrifuged in bulks of four at 1000 rpm. minute for 3 minutes. The liquid fraction is discarded. Using a three-way tap system, the adipose tissue is microfragmented between two 10 ml syringes by moving the contents back and forth at least 20 times. The adipose tissue is then distributed in 2 ml syringes for injection. A total of between 25 and 55 ml of usable adipose tissue will be harvested.
Study NCT05830734 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bascoms Cleft lift procedure
Description: The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
Study NCT05830734 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bascoms Cleft lift procedure
Description: The procedure is carried out according to standardized principles previously decribed by Drs. John and Tom Bascom
Study NCT05830136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sodium bicarbonate Ringer's solution
Description: Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
Study NCT05830136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sodium bicarbonate Ringer's solution
Description: Sodium bicarbonate Ringer's solution was used in Group A as intraoperative intravenous fluids. Lactate Ringer's solution was used in Group B as intraoperative intravenous fluids.
Study NCT04796506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progressive Resistance Training (PRT)
Description: PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by >24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).
Study NCT04796506 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Progressive Resistance Training (PRT)
Description: PD subjects may be randomized (1:1) to PRT with supervised sessions 3 times per week for 12 weeks. Exercise training will consist of a combination of resistance training (RT) and bodyweight functional mobility exercises with limited rest intervals. The full volume exercise prescription will consist of: 1) five movements to improve strength and muscle mass each performed for 3 sets of 8-12 repetitions; 2) trunk exercises to improve postural stability; and 3) 3-4 bodyweight exercises to improve power and balance. Change in slow wave sleep (SWS) from baseline to 12-weeks will be used to determine the assignment in the second 12-week period. Subjects with an increase in SWS by >24 minutes will continue in PRT for the 2nd 12 weeks of the trial, while participants with \<24 minutes increase in SWS will transition to endurance training (ET).
Study NCT04796506 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Delayed Exercise Training (DE)
Description: PD subjects randomized to the exercise control group (1:1) will not exercise during the first 12 weeks of the study. During that time, they will be asked not to change their physical activity levels or dietary habits. All participants in the delayed-exercise group will begin PRT at completion of the 1st 12-week period.
Study NCT06767917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyefill® S.C.
Description: Used as viscoelastic devices during cataract surgery
Study NCT06767917 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eyefill® M.B.
Description: Used as viscoelastic devices during cataract surgery
Study NCT06766097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: mastic toothpaste
Description: All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
Study NCT06766097 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo toothpaste
Description: All 30 patients will be randomly assigned to either the mastic toothpaste group A (Mastiha Toothpaste Gingivaction, Mastihashop, Greece) (n = 15) or the placebo Toothpaste group B (from the same manufacturer) (n = 15). All patients will be asked to use the toothpaste triple a day for 14 days and to maintain their usual oral hygiene routine. The measurements will be done in the morning and at least three hours after brushing and without the use of the toothpaste by the participant on the day of the assessments.
Study NCT05021965 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: different combined of tooth bleaching procedure
Description: The participants will be randomly allocated into 4 groups and receive different kind of tooth bleaching protocol.
Study NCT06765473 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: preoperative vaginal and postoperative sublingual administration of misoprostol (800 μg) to reducing the amount of blood loss during and 24 hours after CS to determine the optimum time for drug administration.
Study NCT06765694 — intervention group
Intervention type: DRUG
Intervention: Botulinum toxin injection
Description: first injection was done under ultrasound control in the extensor carpi radialis brevis (ECRB). The second one if necessary was subordinated to clinical examination and focused in one or more of the following: ECRB, extensor digitorum communis, supinator.
Study NCT06765031 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Furosemide
Description: Furosemide will be administered intravenously in the form of a push at a dose of 1 mg/kg to furosemide-naïve patients who meet the inclusion criteria and at a dose of 1.5 mg/kg to patients exposed to furosemide.
Study NCT06766448 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: robotic training
Description: a rehabilitation program combining continuous passive mobilization, robotic therapy and self-program booklet
Study NCT06766448 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventionnal rehabilitation
Description: rehabilitation sessions include pain-relieving physiotherapy, passive mobilization, active functional work, and self-programmed learning with a physiotherapist
Study NCT06765135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Clinician Survey
Description: At the conclusion of the intervention period, practice stakeholders, including survey providers and practice managers in the intervention sites will be surveyed to identify their degree of satisfaction with the intervention and suggestions for improvement.
Study NCT06765135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Focus Group
Description: Prior to installing the device in each primary care practice, trained moderators will conduct focus groups with clinicians and practice staff to to elicit provider perceptions of POC testing for respiratory pathogens, including feasibility and acceptability of integration of testing into routine workflows.
Study NCT06765135 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biofire Spotfire Respiratory (R) panel
Description: Eligible patients will be offered testing with the BioFire Spotfire Respiratory (R) Panel, which is an FDA-cleared, CLIA waived test. This is a multiplexed polymerase chain reaction (PCR) test intended for use with the BioFire Spotfire System for the simultaneous, qualitative detection and identification of multiple respiratory viral and bacterial nucleic acids in nasopharyngeal (NP) swab specimens obtained from individuals with signs and symptoms of respiratory tract infection, including COVID-19. This testing will be made available in participating practices along with clinical guidance about use and interpretation. Clinicians will administer the tests to patients who agree to be tested. Results will be shared with patients, who can discuss the results with their clinicians. Clinicians can use the test results to guide their treatment decisions.
Study NCT06765135 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Patient Survey
Description: During the intervention period, patients who undergo POC RPP testing will be surveyed soon after their visit to elicit their opinions about the test.
Study NCT06767995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flexible fiberoptic bronchoscopy
Description: If Flexible Intubation Video Endoscope® (FIVE) will be used, the appropriate endotracheal tube is loaded into the bronchoscope and made ready. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started when the FFB started to pass through the patient's mouth/nose, and as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, the stopwatch was stopped and this time was recorded as the successful intubation time. The time between passing FFB through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. The endotracheal tube passage time was defined as the intubation time minus the best glottic visualization time and recorded. Complications during the procedure were recorded.
Study NCT06767995 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Glidescope
Description: If GlideScope® Titanium is to be used, a 50-60° angle is applied with the appropriate stylet, and the appropriate one from 3 pediatric blade sizes is selected according to the clinical experience of the relevant practitioner. The number of attempts and duration of successful intubation were recorded by a non-blinded research assistant. The stopwatch was started as soon as the videolaryngoscope started to pass through the patient's mouth, and the stopwatch was stopped as soon as the ventilation of the lungs was confirmed by the end tidal carbon dioxide trace, and this time was recorded as the successful intubation time. The time between passing the videolaryngoscope through the mouth/nose and obtaining the best glottic view was recorded as the best glottic visualization time. Endotracheal tube transit time was defined as intubation time minus best glottic visualization time and recorded. Complications during the procedure were recorded.
Study NCT06765564 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: iPSC-MNP
Description: Using iPSC-MNP Cells for the Treatment of ALS Patients
Study NCT06769802 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental
Description: The children in this group and their mothers will be informed about the research and their written consent will be obtained. The scale will be filled in before the application. Before the application, Nebul will introduce the teddy bear to the mother and child. The teddy bear cannot be washed because it contains an electronic device. Therefore, it will be disinfected with a solution containing 60-70% alcohol before and after use. The recorded voice will then be played to the child and mother. Then, routine nebulizer treatment will be applied and the second audio recording will be played at the end of the treatment. The researcher will be with the child.~At the end of the nebulizer treatment, after the mask is removed, the Child Fear Scale and the Child Anxiety Scale-State Scale will be filled out. The Child Fear Scale will be filled in by both the mother and the nurse and the average will be taken.
Study NCT06769802 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: The children in this group and their parents will be informed about the research and their written consent will be obtained. Scales will be filled in before application. Children in this group will receive routine nebulizer treatment and routine application will be performed. At the end of the treatment, the scales will be filled in again.
Study NCT06769503 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aromatherapy
Description: Lavender oil dropped on gauze will be smelled for approximately 3-5 minutes.
Study NCT06768307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC
Description: Cohort 1:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Concurrent Radiotherapy Phase: the fourth cycle will incorporate concurrent radiotherapy along with atezolizumab and chemotherapy.~Maintenance Phase: Atezolizumab monotherapy will be administered until disease progression or intolerance by the patient, with atezolizumab being administered for a maximum duration of 2 years.~Cohort 2:~Induction Phase: Patients will receive three cycles of atezolizumab in combination with carboplatin/cisplatin plus etoposide.~Sequential Radiotherapy Phase: the fourth cycle will receive sequential radiotherapy in combination with atezolizumab.Final，Atezolizumab monotherapy will be continued until disease progression.
Study NCT06767501 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: E-GRAFT ™
Description: E-GRAFT™ that is a dehydrated thick amniotic allograft processed and approved for use as a Human Cellular and Tissue-Based Product (HCT/P) under FDA 21 CFR 1271 and Section 361 of the Public Health Service (PHS) Act.
Study NCT06767501 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FIBRACOL™
Description: 510K FDA cleared Collagen alginate dressing
Study NCT06765525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Junior sonographer measurement of DDH
Description: Participants will not receive visual cues from the DeepDDH system. Junior sonographer technicians will offer preliminary interpretations before these are subjected to validation and subsequent review by expert's team.
Study NCT06765525 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Senior sonographer measurement of DDH
Description: Participants will not receive visual cues from the DeepDDH system.
Study NCT06765525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Automated annotation of the DDH measurement through deep learning
Description: Through randomization, a subset of the preliminary interpretations will be conducted by AI technology, and the study team will evaluate the degree of divergence between these AI-generated preliminary interpretations and the final interpretations.
Study NCT06765525 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI-assisted junior sonographer meaturement of DDH
Description: Participants will receive visual cues from the DeepDDH system.
Study NCT06763783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Shingrix
Description: all participants vaccinates with two doses of Shingrix vaccine
Study NCT06763783 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: vaccination with 2 doses of Shingrix vaccine
Description: all participants will receive vaccination with 2 doses of Shingrix vaccine. The response to caccine will be compared bitween patients treated with immunosupressive drugs and these not receiving immunosuppresive treatment
Study NCT06769152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 1
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06769152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 2
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06769152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX43 DOSE 3
Description: HLX43 is an anti-PD-L1 monoclonal antibody conjugated with a novel high potency DNA topoisomerase I (topo I) inhibitor, with a drug-antibody-ratio (DAR) of 8.
Study NCT06767696 — intervention group
Intervention type: OTHER
Intervention: Cuff pressure measurement
Description: Intubation tube cuff pressure in cmH2O at 3 different time periods with a cuff manometer (VBM Medizintechnik, GmbH, Germany)~Time periods:~Cuff pressure value measured in neutral position after intubation (cmH2O) - T0 Cuff pressure measurement value after hyperextension (cmH2O) - T1 Cuff pressure measurement value in neutral position after surgical procedure (cmH2O) - T2
Study NCT06769854 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Urgent PC
Description: PTNS is a technique of electrical neuromodulation used primarily for treating OAB. The procedure for PTNS consists of the insertion of a fine needle above the medial malleolus near the posterior tibial nerve followed by the application of low-voltage electrical stimulation that produces sensory and motor responses.
Study NCT06768801 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: WPAPP-Latina
Description: The WPAPP Latina intervention provides 1) educational information via modules and online resources and 2) coaching via an online forum with a chat function. The educational modules include 11 modules on physical activity promotion and 7 modules on depressive symptoms. The women are also invited to share their experiences with culturally matched interventionists (e.g., Spanish speaking graduate research assistant with expertise in depressive symptoms and physical activity) and with peer participants using a de-identified name in the online chat forum. Participants will be directed to information about physical activity with age-appropriate guidelines from the Centers for Disease Control and Prevention.
Study NCT06765954 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803 (IL-15 Superagonist)
Description: Administered subcutaneously (SC) both before and after radiation therapy. The specific dosing schedule varies slightly depending on the cohort.